Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
Globe Newswire•12/11/2026•16:30 ET
1
Key Highlights
- ➤$142.2 million cash, equivalents and securities supports operations into first half of 2028
- ➤STRO-006 enters Phase 1 after first patient dosed; initial data expected second half of 2027
- ➤STRO-227 Phase 1 trial initiation targeted for early 2027
- ➤Astellas B7-H3 program dosing triggers $10 million milestone payment to Sutro
- ➤Third-quarter revenue $9.1 million versus $9.7 million year over year
- ➤Third-quarter R&D and G&A expenses fall to $31.0 million from $48.6 million
Expert Statements
Jane Chung, Chief Executive Officer of Sutro Biopharma
“Over the past year, we have delivered on our commitment to advance our next-generation ADCs with two programs, STRO-004 and STRO-006, entering the clinic in less than a year, and our dual-payload ADC, STRO-227, expected to follow in early 2027”
Jane Chung, Chief Executive Officer of Sutro Biopharma
“Early data from STRO-004 give us confidence in its potential to deliver meaningful clinical benefit with our proprietary ADC platform.”
Jane Chung, Chief Executive Officer of Sutro Biopharma
“In addition, our collaboration partner Astellas has initiated patient dosing with a second dual-payload immunostimulatory ADC, further highlighting our strong execution and ability to deliver differentiated, novel dual-payload ADCs.”
Jane Chung, Chief Executive Officer of Sutro Biopharma
“Together these advances reflect our proficiency in translating platform innovation into a growing pipeline of therapies designed to improve patient outcomes and create long-term value.”
– STRO-004, TF-targeting ADC, Phase 1 STRIVE-01 study advancing; next clinical update and initiation of expansion cohorts planned first half of 2027 –
– STRO-006, ITGB6-targeting ADC, enters clinic with first patient dosed; initial update expected second half of 2027 –
Get started
Create a free account to read the full story.